Inhibition of Immune-mediated Low-dose Streptozotocin Diabetes by Agents Which Reduce Vascular Permeability

Overview

Journal Immunopharmacology

Specialty Allergy & Immunology

Date 1986 Aug 1

PMID 3531086

Citations 5

Authors

E Schwab

V Burkart

G FREYTAG

U Kiesel

H Kolb

Affiliations

Soon will be listed here.

Abstract

Low-dose streptozotocin treatment in C57Bl/6J mice causes development of hyperglycemia within two weeks. Diabetes development is due to the specific loss of beta cells from pancreatic islets which can be blocked by immunosuppressive treatment. The role of vascular permeability in pancreatic islet destruction was studied by administration of methysergide or pargyline in addition to low-dose streptozotocin. Both drugs impair serotonin-enhanced vascular permeability. Administration of methysergide or pargyline during the first 11 days following streptozotocin treatment caused substantial suppression of diabetes development. These observations suggest a role of enhanced vascular permeability in immune-mediated beta cell destruction.

Citing Articles

IL-1 and IFN-gamma increase vascular permeability.

Martin S, Maruta K, Burkart V, Gillis S, Kolb H Immunology. 1988; 64(2):301-5.

PMID: 3134297 PMC: 1384958.

The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes induced by multiple low doses of streptozotocin in the mouse.

Jansson L, Sandler S Virchows Arch A Pathol Anat Histopathol. 1988; 412(3):225-30.

PMID: 3124343 DOI: 10.1007/BF00737146.

Pathogenesis of low dose streptozotocin induced diabetes in mice: requirement for alpha 1-adrenoceptor activation and vasoactive amine release.

Martin S, Kolb-Bachofen V, Kiesel U, Kolb H Diabetologia. 1989; 32(2):140-2.

PMID: 2542109 DOI: 10.1007/BF00505187.

Capillary area in early low-dose streptozocin-treated mice.

Papaccio G, MEZZOGIORNO V, Esposito V Histochemistry. 1990; 95(1):19-21.

PMID: 1704876 DOI: 10.1007/BF00737223.

Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro.

Burkart V, Koike T, BRENNER H, Kolb H Diabetologia. 1992; 35(11):1028-34.

PMID: 1473612 DOI: 10.1007/BF02221677.